Opening this trial suggests continued institutional confidence in the broader platform and safety profile, but for an academic trial it looks unusually conservative looking at the number they plan to enrol and the (primary) endpoint. As for the exclusion criteria (prior bevacizumab or cellular therapy), it could reflect concerns around immune effects, confounding interpretation, wound healing, and/or edema.
I think the trials (including another in recurrent ovarian, fallopian tube, and primary peritoneal cancers also using FT536) will feed directly back into the next-gen iPSC engineering strategy that the U of M has a number of grants for like this https://reporter.nih.gov/search/d9lW8yEhyEKJeSffPzNN6Q/project-details/11158564
Market Data 
Markets 
